81 participants
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-06-08
- Start Date:
- 2019-11-18
- Completion:
- 2026-06-30
Conditions
- Part 1:r/r B-cell Malignancies
- Part 2:B-cell Malignancies
Interventions
- DRUG
No Results Yet